by 
Antibody drug conjugates (ADCs) are biopharmaceutical drugs designed with an antibody linked to a potent cytotoxic drug with a stable linker. The antibody acts as a targeted delivery system for the cytotoxic drug to specific cells, thereby reducing toxic effects on non-cancerous cells. ADCs take advantage of the ability of antibodies to specifically bind to cell surface receptors or antigenes present in substantial quantities on tumor cells. The linker is designed to be stable in the bloodstream, while readily releasing the cytotoxic drug after being internalized by antigen-positive tumor cells. Some key advantages of ADCs include improved safety, efficacy, and targeted cancer cell killing while sparing most healthy cells from chemotherapy.
The global Antibody Drug Conjugates Market is estimated to be valued at US$ 5.38 Bn in 2023 and is expected to exhibit a CAGR of 14 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the Antibody drug conjugates market is the increasing number of ADC candidates in pipeline. As of 2020, there were over 50 ADC candidates in active clinical development with over 1200 clinical trials registered for evaluating ADC therapeutics. Majority of these candidates are in phase 1 and 2 of clinical trials. The increasing R&D investment by biotech and pharma companies to develop new ADC candidates with improved linker-payload profiles is expected to drive the market growth during the forecast period. Additionally, emerging technologies like conjugation strategies, site-specific conjugation, prodrug strategies are also influencing the drug development to improve efficacy and safety of ADCs.
Porter’s Analysis
Threat of new entrants: The requirement of large capital investments in Research and Development along with strict regulatory environment acts as a barrier for new players to enter the market.
Bargaining power of buyers: The presence of large number of players operating in the market gives buyers options to choose from different products based on their need and price which increases their bargaining power.
Bargaining power of suppliers: Due to specialized nature of drugs, suppliers have moderate bargaining power against companies operating in the market.
Threat of new substitutes: Scarcity of novel therapeutic options increases the demand for antibody drug conjugates thereby reducing the threat of substitutes.
Competitive rivalry: Intense competition exists among the key players to gain higher market share.
Key Takeaways
The global Antibody Drug Conjugates market is expected to witness high growth, exhibiting a CAGR of 14% over the forecast period, due to increasing prevalence of cancer globally.
Regional analysis: North America dominated the global Antibody Drug Conjugates market in 2023 and is expected to maintain its lead over the forecast period. This is attributed to the rising cases of cancer, growing demand for advanced therapies, and presence of key market players in the region. Meanwhile, Asia Pacific is anticipated to grow at the fastest pace during the forecast period owing to huge patient population, increasing healthcare spending, and growing awareness.
Key players: Key players operating in the Antibody Drug Conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd. Intense competition exists among these players to gain a higher market share through product launches, partnerships, and expansions.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
